|
|
|
|
Males
(n)
|
Females (n)
|
|
Malandraki et al. 2016
Level 4
|
USA
|
Pre-Post
|
Stroke=6
TBId=2
Other=2
|
8
|
2
|
64.6
|
Seedat & Penn 2016
Level 2
|
South Africa
|
PCTe
|
Stroke=32
TBIc=14
|
23
|
23
|
N/Sf
|
Terre & Mearin 2015
PEDroa=7, Level 1b
|
Spain
|
RCTg
|
Stroke=14
TBId=6
|
12
|
8
|
CGh: 51
IGi: 46
|
Terre & Mearin 2012
PEDroa=5, Level 2
|
Spain
|
RCTg Crossover
|
Stroke=45
TBId=27
|
50
|
2
|
CGh: 51
IGi: 43
|
Seidl et al. 2007
Level 4
|
Germany
|
Pre-Post
|
Stroke=8
TBId=2
|
6
|
4
|
39.7
|
Clave et al. 2006
Level 4
|
Spain
|
Post-Test
|
Stroke=24
TBI=22
Other=46
|
62
|
38
|
CGh: 40.31
IGi: 41.92
|
Martens et al. 1990
Level 2
|
Canada
|
PCTe
|
Stroke=11
TBId + ABIc = 7
Other=13
|
17
|
14
|
CGh: 46.1
IGi: 49.3
|
Ko et al. 2016
Level 2
|
South Korea
|
PCTe
|
Stroke=16
TBId=2
|
12
|
6
|
CGh: 60
IGi: 72
|
Toyama et al. 2014
Level 2
|
Japan
|
PCTe
|
Stroke=22
ABIc=4
|
22
|
4
|
CGh: 57.2
IGi: 63.6
|
Calabro et al. 2016
Level 5
|
Italy |
Case Report |
TBId=1 |
1 |
0 |
34 |
Levitan & Henderson 2015
Level 4
|
USA
|
Post-Test (Conference Abstract)
|
Mod-Sev ABIc=38
|
N/Se
|
N/Se
|
N/Se
|
Steele et al. 2013
Level 4
|
Canada
|
Pre-Post
|
TBId=6
|
n=4
|
n=2
|
42.3
|
Yuen & Hartwick 1992
Level 5
|
USA
|
Case Report
|
TBId=1
|
n=1
|
n=0
|
53
|
Cassel 2016
Level 2
|
USA
|
RCTg (Conference Abstract)
|
Stroke + TBId =30
|
N/Sf
|
N/Sf
|
Range: 65-90
|
Beom et al. 2015
PEDroa=8, Level 1b
|
South Korea
|
RCTg
|
Stroke + TBId + ABIc =132
|
n=77
|
n=55
|
CGh: 64.4
IGi: 59.8
|
Nam et al. 2013
PEDroa=5, Level 2
|
South Korea
|
RCTg
|
Stroke, TBId =50
|
n=26
|
n=23
|
CGh: 62.3
IGi: 60.9
|
Kojima et al. 2002
Level 4
|
Japan
|
Post-Test11
|
ABI=12
Other=65
|
n=47
|
n=17
|
66.4
|
Note: aPhysiotherapy Evidence Database (PEDro);
bLevel of evidence (LOE); cAcquired
brain injury (ABI); dTraumatic brain injury (TBI);
eProspective Controlled Trial (PCT);
fNot specified (N/S); gRandomized
controlled trial; hControl group (CG);
iIntervention group (IG);
jAmyotrophic lateral sclerosis (ALS);
kMultiple sclerosis (MS). |
Note:
aPhysiotherapy Evidence Database (PEDro);
bLevel of evidence (LOE); cAcquired
brain injury (ABI); dTraumatic brain injury (TBI);
eProspective Controlled Trial (PCT);
fNot specified (N/S); gRandomized
controlled trial; hControl group (CG);
iIntervention group (IG);
jAmyotrophic lateral sclerosis (ALS);
kMultiple sclerosis (MS). |
Note:
aPhysiotherapy Evidence Database (PEDro);
bLevel of evidence (LOE); cAcquired
brain injury (ABI); dTraumatic brain injury (TBI);
eProspective Controlled Trial (PCT);
fNot specified (N/S); gRandomized
controlled trial; hControl group (CG);
iIntervention group (IG);
jAmyotrophic lateral sclerosis (ALS);
kMultiple sclerosis (MS). |
Note:
aPhysiotherapy Evidence Database (PEDro);
bLevel of evidence (LOE); cAcquired
brain injury (ABI); dTraumatic brain injury (TBI);
eProspective Controlled Trial (PCT);
fNot specified (N/S); gRandomized
controlled trial; hControl group (CG);
iIntervention group (IG);
jAmyotrophic lateral sclerosis (ALS);
kMultiple sclerosis (MS). |
Note:
aPhysiotherapy Evidence Database (PEDro);
bLevel of evidence (LOE); cAcquired
brain injury (ABI); dTraumatic brain injury (TBI);
eProspective Controlled Trial (PCT);
fNot specified (N/S); gRandomized
controlled trial; hControl group (CG);
iIntervention group (IG);
jAmyotrophic lateral sclerosis (ALS);
kMultiple sclerosis (MS). |
Note:
aPhysiotherapy Evidence Database (PEDro);
bLevel of evidence (LOE); cAcquired
brain injury (ABI); dTraumatic brain injury (TBI);
eProspective Controlled Trial (PCT);
fNot specified (N/S); gRandomized
controlled trial; hControl group (CG);
iIntervention group (IG);
jAmyotrophic lateral sclerosis (ALS);
kMultiple sclerosis (MS). |
Note:
aPhysiotherapy Evidence Database (PEDro);
bLevel of evidence (LOE); cAcquired
brain injury (ABI); dTraumatic brain injury (TBI);
eProspective Controlled Trial (PCT);
fNot specified (N/S); gRandomized
controlled trial; hControl group (CG);
iIntervention group (IG);
jAmyotrophic lateral sclerosis (ALS);
kMultiple sclerosis (MS). |